<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02735577</url>
  </required_header>
  <id_info>
    <org_study_id>7193</org_study_id>
    <nct_id>NCT02735577</nct_id>
  </id_info>
  <brief_title>Neural Mechanisms of Disulfiram Effects</brief_title>
  <official_title>Neurocognitive Mechanisms of Disulfiram Treatment of Alcohol Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study combines functional MRI with medication treatment in order to understand the&#xD;
      neural mechanisms by which disulfiram, a currently approved medication for alcohol use&#xD;
      disorder, changes behavior. Disulfiram is a medication that prevents drinking by causing a&#xD;
      highly unpleasant physical reaction when alcohol is consumed while it is being taken. Thus,&#xD;
      it provides a means for studying the general neural mechanisms by which awareness of risks&#xD;
      impacts behavior change in alcohol use disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall goal of this project is to combine functional brain imaging and clinical methods&#xD;
      in order to examine how treatment with disulfiram (DIS) alters neural activity related to&#xD;
      alcohol-seeking motivation in patients with alcohol use disorder (AUD). DIS is an&#xD;
      established, effective, FDA-approved medication for AUD that causes a highly aversive&#xD;
      physical reaction if alcohol is consumed while it is being taken. The mere awareness of the&#xD;
      risk or threat the DIS-alcohol reaction deters alcohol use, i.e. it is not necessary to drink&#xD;
      alcohol while taking DIS to change behavior. By uncovering the neural mechanisms underlying&#xD;
      this risk/threat-based psychological effect, it will be possible to integrate DIS with&#xD;
      biologically based treatments targeted at these neural mechanisms, with the goal of improving&#xD;
      the efficacy of DIS. Furthermore, the results will shed light on the general neural&#xD;
      mechanisms by which awareness of risks of substance use impacts addictive motivation. This is&#xD;
      a core process in a number of behavioral treatments for substance use disorders, such as&#xD;
      Motivational Interviewing and Contingency Management, as well as in behavior change in&#xD;
      non-treatment settings.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">October 16, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alcohol Use</measure>
    <time_frame>42 days</time_frame>
    <description>Number of drinking days</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Disulfiram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive disulfiram 250 mg daily for a total of 40 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Disulfiram</intervention_name>
    <description>Patients will be hospitalized on an inpatient psychiatric unit for 1-7 days to initiate abstinence. An fMRI scan will be performed to examine neural mechanisms of alcohol motivation. Prior to discharge, patients will receive the first dose of disulfiram 500 mg. They will then attend an outpatient clinic every other day for 14 days. At each clinic visit, they will receive 500 mg of disulfiram under supervision. Another fMRI scan examining alcohol motivation will be performed. Following this, all patients will attend the clinic weekly, and will be prescribed disulfiram 250 mg daily to take at home. This will be followed followed by an optional extension of weekly visits taking disulfiram 250 mg daily for another 28 days, for a total of 70 days of disulfiram treatment.</description>
    <arm_group_label>Disulfiram</arm_group_label>
    <other_name>Antabuse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between the ages of 21-60&#xD;
&#xD;
          2. Right-handed&#xD;
&#xD;
          3. Capable of giving informed consent and complying with study procedures&#xD;
&#xD;
          4. Reports drinking a minimum of 5 standard drinks for men or 4 standard drinks for women&#xD;
             on at least 4 days per week on average over the past 28 days&#xD;
&#xD;
          5. Meets DSM-V criteria for current Alcohol Use Disorder&#xD;
&#xD;
          6. Seeking treatment for Alcohol Use Disorder&#xD;
&#xD;
          7. Agree to not seek additional treatment, apart from Alcoholics Anonymous&#xD;
&#xD;
          8. Willing to attempt to abstain from alcohol completely for the duration of the study&#xD;
&#xD;
          9. Willing to be hospitalized on a research unit for 24 hours, longer if detoxification&#xD;
             is needed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Risk of severe alcohol withdrawal (e.g. history of seizures or delirium tremens)&#xD;
&#xD;
          2. Current Moderate or Severe Substance Use Disorder, other than Alcohol, Nicotine or&#xD;
             Caffeine Use Disorders&#xD;
&#xD;
          3. Lifetime history of Bipolar Disorder, Schizophrenia or Schizoaffective Disorder&#xD;
&#xD;
          4. Any current psychiatric disorder, other than Alcohol Use Disorder, that, in the&#xD;
             judgment of the investigator, will require treatment that will interfere with study&#xD;
             participation.&#xD;
&#xD;
          5. Current severe depression (HAM-D &gt;24) or anxiety (HAM-A &gt;24)&#xD;
&#xD;
          6. Significant suicide or violence risk&#xD;
&#xD;
          7. Currently taking any psychotropic medications&#xD;
&#xD;
          8. Legally mandated to participate in treatment&#xD;
&#xD;
          9. History of prior treatment with disulfiram&#xD;
&#xD;
         10. Sufficiently socially unstable as to preclude participation (e.g. homeless)&#xD;
&#xD;
         11. Contraindications to disulfiram treatment (liver disease, kidney disease, cardiac&#xD;
             disease, seizure disorder, hypothyroidism, diabetes mellitus, pregnancy or lactation,&#xD;
             allergy to disulfiram or thiuran derivatives)&#xD;
&#xD;
         12. Neurological or medical conditions that would interfere with MRI scanning (e.g.&#xD;
             history of stroke, seizure, brain tumor, brain infection, traumatic brain injury,&#xD;
             multiple sclerosis, dementia, metal device in body, pregnancy, claustrophobia, color&#xD;
             blindness, severe hearing impairment, weight&gt;300 lbs., wheelchair-bound)&#xD;
&#xD;
         13. Currently taking medications containing alcohol, metronidazole, isoniazid,&#xD;
             paraldehyde, phenytoin, warfarin, or theophylline.&#xD;
&#xD;
         14. Significant alcohol withdrawal (CIWA&gt;8) at screening, after confirming a blood alcohol&#xD;
             level of zero.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nasir H. Naqvi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYP Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYPInstitute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 6, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <results_first_submitted>October 29, 2020</results_first_submitted>
  <results_first_submitted_qc>October 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 23, 2020</results_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Nasir Naqvi</investigator_full_name>
    <investigator_title>research psychiatrist</investigator_title>
  </responsible_party>
  <keyword>Alcohol</keyword>
  <keyword>Craving</keyword>
  <keyword>Functional MRI</keyword>
  <keyword>Cognitive control</keyword>
  <keyword>Risky decision-making</keyword>
  <keyword>Disulfiram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disulfiram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 26, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02735577/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 14, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02735577/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Disulfiram</title>
          <description>Patients in this arm will receive disulfiram 250 mg daily for a total of 42 days.&#xD;
Disulfiram: Patients will be hospitalized on an inpatient psychiatric unit for 1-7 days to initiate abstinence. An fMRI scan will be performed to examine neural mechanisms of alcohol motivation. Prior to discharge, patients will receive the first dose of disulfiram 500 mg. They will then attend an outpatient clinic every other day for 14 days. At each clinic visit, they will receive 500 mg of disulfiram under supervision. Another fMRI scan examining alcohol motivation will be performed. Following this, all patients will attend the clinic weekly, and will be prescribed disulfiram 250 mg daily to take at home. This will be followed followed by an optional extension of weekly visits taking disulfiram 250 mg daily for another 28 days, for a total of 70 days of disulfiram treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Disulfiram Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Optional 28 Days of Disulfiram Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Enrolled Participants</population>
      <group_list>
        <group group_id="B1">
          <title>Disulfiram</title>
          <description>Patients in this arm will receive disulfiram 250 mg daily for a total of 42 days.&#xD;
Disulfiram: Patients will be hospitalized on an inpatient psychiatric unit for 1-7 days to initiate abstinence. An fMRI scan will be performed to examine neural mechanisms of alcohol motivation. Prior to discharge, patients will receive the first dose of disulfiram 500 mg. They will then attend an outpatient clinic every other day for 14 days. At each clinic visit, they will receive 500 mg of disulfiram under supervision. Another fMRI scan examining alcohol motivation will be performed. Following this, all patients will attend the clinic weekly, and will be prescribed disulfiram 250 mg daily to take at home. This will be followed followed by an optional extension of weekly visits taking disulfiram 250 mg daily for another 28 days, for a total of 70 days of disulfiram treatment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.6" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Drinking days (prior 28 days)</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.0" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Alcohol Use</title>
        <description>Number of drinking days</description>
        <time_frame>42 days</time_frame>
        <population>Participants who completed the initial 42 days of disulfiram treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Disulfiram</title>
            <description>Patients in this arm will receive disulfiram 250 mg daily for a total of 42 days.&#xD;
Disulfiram: Patients will be hospitalized on an inpatient psychiatric unit for 1-7 days to initiate abstinence. An fMRI scan will be performed to examine neural mechanisms of alcohol motivation. Prior to discharge, patients will receive the first dose of disulfiram 500 mg. They will then attend an outpatient clinic every other day for 14 days. At each clinic visit, they will receive 500 mg of disulfiram under supervision. Another fMRI scan examining alcohol motivation will be performed. Following this, all patients will attend the clinic weekly, and will be prescribed disulfiram 250 mg daily to take at home. This will be followed followed by an optional extension of weekly visits taking disulfiram 250 mg daily for another 28 days, for a total of 70 days of disulfiram treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Alcohol Use</title>
          <description>Number of drinking days</description>
          <population>Participants who completed the initial 42 days of disulfiram treatment</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>42 days of initial disulfiram treatment or length of participation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Disulfiram</title>
          <description>Patients in this arm will receive disulfiram 250 mg daily for a total of 42 days.&#xD;
Disulfiram: Patients will be hospitalized on an inpatient psychiatric unit for 1-7 days to initiate abstinence. An fMRI scan will be performed to examine neural mechanisms of alcohol motivation. Prior to discharge, patients will receive the first dose of disulfiram 500 mg. They will then attend an outpatient clinic every other day for 14 days. At each clinic visit, they will receive 500 mg of disulfiram under supervision. Another fMRI scan examining alcohol motivation will be performed. Following this, all patients will attend the clinic weekly, and will be prescribed disulfiram 250 mg daily to take at home. This will be followed followed by an optional extension of weekly visits taking disulfiram 250 mg daily for another 28 days, for a total of 70 days of disulfiram treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>fMRI data analysis is not complete because there are not enough subjects to produce valid data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Nasir Naqvi, MD</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>6467748181</phone>
      <email>nasir.naqvi@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

